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Heart Centre Singapore between August 2017 and November 2017.
All enrolled patients had CTCA performed on a Toshiba Aquilion One
320-slice CT scanner which was further analysed using Vitrea software.
Demographic and clinical informations including relevant investiga-
tions were recorded and statistical analysis was performed.
Results: Majority (58.3%, n=326) of the patients in this study
are male with the mean age (±SD) of 55.35 (12.1) years old. Of these
560 patients, 97 (17.3%) was found to have myocardial bridging by
CTCA. Majority (n=95) of the bridges was found in LAD, three was
found in right coronary artery, and one in ramus intermedius artery.
Of the 97 patients with myocardial bridging by CTCA, 26 underwent
angiogram and 6 was confirmed to have bridging by angiogram
procedure. There was no statistically significant association between
patients' demographywith the presence ofmyocardial bridging by CTCA.
Conclusion: The prevalence of myocardial bridging found by CTCA
in this study was 17.3% with no significant association between
patients' demography and the presence of myocardial bridging.
doi:10.1016/j.ijcard.2018.11.065
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Background: The complex changes that occur in the heart during
LV remodeling in response to wall stress cause alterations in LV size
and geometry. However, little is known on how these changes affects
myocardial efficiency. Myocardial work, using echocardiography is
a novel assessment method that augments Automated Functional
Imaging (AFI) by taking into account dynamic left ventricle (LV)
pressure. This adds an important dimension to the assessment and
interpretation of LV function.
Aim: To evaluate patterns of global myocardial work between
physiological and pathological causes of LV hypertrophy.
Method: This was a descriptive single center cross-sectional study.
Conventional two-dimensional (2D) greyscale images of LV apical two-,
four-, and three-chamber views for assessing LV volumes, ejection
fraction (EF), and global longitudinal strain (GLS) by speckle-tracking
were captured during echocardiography. Myocardial work was ana-
lyzed offline using commercial software. Narrow sector 2D imaging
over valves in parasternal long-axis view was used to define timing of
opening and closure of the mitral and aortic valves; this was required
for calculation of an estimated LV pressure curve.
Result: There were 20 normal subjects, 24 professional athletes
and 10 patients with NICM in this cohort. NICM subjects were older
(mean age 55±7.9 years), have lower EF (40±12%), higher LV mass
(317±899) andpseudonormal pattern of diastolic dysfunction (E/A ratio
1.3±0.9). The professional athletes were relatively younger, have higher
LVEF (62±4%), lower LV mass, and supranormal pattern of diastolic
dysfunction (203±579) (2.2±0.4). The mean GLS for the normal
subjects, professional athletes and NICM were 19±2.4%, 20±2,5% and
14±0.7% respectively. The mean global MWI for the normal subjects,
professional athletes and NICM were 1901±355 mmHg%, 1931±
485 mmHg%, 723 ±431 mmHg%. The NICM has more global wasted
work and less global constructive work compared to the normal and
athletes (351±179 mmHg% vs 180±53 mmHg% vs 119±97 mmHg%
and 1187±322 mmHg% vs 1562±248 mmHg% vs 2170±483 mmHg%).
Conclusion: Increased LV mass may not translate into better
myocardial work in a diseased myocardium.
doi:10.1016/j.ijcard.2018.11.066
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Background: With advances in surgery and interventional tech-
niques for patients with congenital heart disease or valvular heart
disease, survival into adulthood has improved. Clinicians caring for
them also face the added challenges of maternal physiology during
pregnancy. Due to lack of local data, clinicians often face uncertainties in
managing them. Hence the need for a local registry.
Material & methods: Data is analysed from a single centre
registry in Malaysia from 1st September 2015 to 31st December 2017.
Pregnantmothers whowere diagnosed to have structural heart disease
(congenital, ischemic heart disease, valvular or cardiomyopathy)
during pregnancywere included in this prospective registry. Immediate
and follow up (at first and six months) outcomes for both mother and
baby were recorded.
Results: A total of 50 patients were recruited with 20 patients
(40%) being primigravida with mean age of 30.9 (+/5.6) years old.
Twenty-eight patients (56%) had congenital heart disease, 18 patients
(36%) had valvular heart disease, 2 patients (4%) had ischemic heart
disease and the rest (4%) had cardiomyopathy. Ventricular septal defect
(13 patients) and atrial septal defect (9 patients) were the common
forms of congenital heart disease. On the other hand, mitral regurgita-
tion (11 patients) and mitral stenosis (3 patients) were the common
valvular heart disease. Most of them (92%) were in NYHA class I and
delivered vaginally (54.0 %). There was no maternal mortality. Most
babies were delivered near term with a mean weight of 2.96 (±0.39)
kg. A total of five fetal losses were noted with two delivered from
motherswith congenital heart disease and two in patientswith valvular
heart disease. Another fetal loss occurred in a patient with coronary
artery disease. There was a 2% mortality at six months due to infective
endocarditis.
Conclusion: Congenital heart disease (septal defects) is the most
common form of structural heart disease while mitral valve disease is
the commonest valvular heart disease. There is no postpartum
mortality within 42 days. However, therewas amortality at sixmonths.
Fetal loss was 10% among mothers with structural heart disease.
doi:10.1016/j.ijcard.2018.11.067
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Background: Delayed enhancement cardiovascular magnetic
resonance imaging (DeCMRI) has become the preferred method for
viability assessment. It is well established that viable dysfunctional
myocardium has the potential for functional recovery after revascu-
larization.
Objective: Our objective is to evaluate whether viability assess-
ment by DeCMRI affects clinical outcome in daily clinical practice.
Methodology:We retrospectively studied 132 consecutive patients
(114 male, mean age 59 ± 10 years) with ischaemic cardiomyopathy
(Mean LVEF: 29.1 ± 14%) who underwent CMRI viability testing from
1st Jan-31st Dec 2015 in our centre. Patientswere divided into 3 groups:
Group A: Viable myocardium- optimal medical therapy only (38.6%);
B: Viable myocardium- revascularization done (29.5%); and C: Non-
viable myocardium (29.5%).
Results: Mean age for groups A, B and C were 61.2, 58.3, 56.2 years
respectively, p=0.048. The proportion of triple vessel disease in each of
the groups were 56.1%, 54.5% and 38.5% (p=0.44); whereas left main
involvement was 31.7%, 21.2% and 19.2% respectively (p=0.43).
Majority of group C patients did not undergo revascularisation (90%).
Group B had statistically significant EF improvement (5.5%, SD 11.9)
compared to Group A (-0.6%, SD 6.7) and Group C (-1.2%, SD 9.8),
p value 0.014. Mortality at 1 year was significantly higher in Group A
compared to Group Band C (31.4%, 7.7% and 12.8% respectively,
p=0.009). MACE rates were also increased in Group A compared
to the other two groups (41.2%, 20.5% and 27.0%, p=0.09). Odds Ratio
for MACEwas 3.01 (95% Cl 1.22 - 7.45) for Group A vs B and 2.8 (95% Cl
1.1 - 6.9) for Group A vs C.
Conclusion: Patients with viable myocardiumwho did not undergo
revascularization (group A) had the worst prognosis, even when
compared to those with non-viable myocardium; with significantly
higher 1-yearmortality. Although not statistically significant, there was
also a trend towards higher MACE in these patients. These findings
emphasize that patients with poor LV function but viable myocardium
need to undergo revascularisation and that optimal medical therapy
alone is not sufficient.
doi:10.1016/j.ijcard.2018.11.068
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Background: Timely reperfusion is critical in ST-segment-
elevation myocardial infarction (STEMI). Current guidelines for STEMI
recommend early revascularization with first medical contact to
coronary intervention is b120 min and door-to-balloon (D2B) time
between 60-90 mins depending on presentation to a PCI or non-PCI
capable hospital. However, this narrow focus does not consider the
substantial duration of myocardial ischemia that exists prior to first
medical contact. Several experimental studies have confirmed that
infarct size and mortality are correlated with the total ischemic time
(IT), that is the time from chest pain to coronary intervention.
Aim: Primary objective of this study was to compare the total IT
to the D2B time as a predictor for short- and long-term mortality.
Methods & results: Between October 2014 and December 2016,
492 patients with STEMI were treated in our STEMI center. Total IT was
defined as time from symptom onset to coronary intervention, while
D2B time was defined as hospital arrival to coronary intervention.
Patients were divided into three groups according to IT (b120 mins
with 36 patients, 120-239 mins with 162 patients, 240 min with
235 patients) and into four groups according to D2B time (b30 mins
with 36 patients, 30-59 mins with 322 patients, 60-89 mins with
94 patients, 90 mins with 40 patients). Baseline demographics
including age, cardiac risk factors, and LAD infarct location were similar
between the IT groups. There was a trend of increasing inpatient
mortality with longer D2B with 1 (3%) mortality for the D2B b 30 mins
group to 3 (8%) in the DBT N 90 mins, although the p value was not
significant (p=0.12). This trend was seen in the total IT group with
no mortality in the total IT b120 mins and 12 (5%) in the total
IT N240mins with p value 0.31. Again, this trend of lower survival with
longer D2B and IT were seen in the 1-year survival from the Kaplan-
meier graph but the p value was not significant for both (PN0.05).
Conclusion: The focus of STEMI care should be directed at the early
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Background: The Ultimaster (Terumo Corporation, Tokyo, Japan)
is a thin-strut, cobalt chromium, biodegradable-polymer sirolimus-
eluting coronary stent. The high elasticity of the biodegradable-
polymer (PDLLA-PCL) and the abluminal gradient coating technology
are additional novel features of this coronary device. The Ultimaster
DES has undergone extensive clinical evaluation in the CENTURY I
and II trials.
Objective: Identify safety and outcome of patients undergoing
percutaneous coronary intervention (PCI) with Ultimaster stent
in Malaysians. Primary endpoint was death at 30-days.
Materials & methods: This was a retrospective, observational
single center study conducted in Cardiovascular and Thoracic Centre
of Universiti Teknologi MARA. All patients undergoing percutaneous
coronary intervention (PCI) with Ultimaster stent from 1st January
2016 until 31st December 2017 were recruited. All relevant
information was then gathered and statistically analyzed. Patients
were followed up at one-month in clinic.
Results: There were 130 patients who underwent PCI with
Ultimaster DES. The mean age was 55.22 (±10.46). 82.3% (n=107)
of the patients were male. Ethnicity breakdown revealed 82 Malays,
30 Chinese, and 15 Indians. Cardiovascular risk assessment showed
53.1% diabetes mellitus, 63.1% smokers, 71.5% hypertension and
63.1% dyslipidemia. Indications for PCI were 64.8% ACS and 35.2%
stable angina. Blood investigation revealed mean fasting blood sugar
of 7.22mmol/L, HbA1c of 7.14%, total cholesterol of 5.11mmol/L,
triglyceride of 1.66mmol/L, HDL of 1.07mmol/L, LDL of 2.90mmol/l
and serum creatinine of 103.37mg/dl. Mean left ventricular ejection
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